Integrative Multi-omics and Network Pharmacology Reveal the Mechanisms of Xiaoyaosan in Treating Depression.

With the continued rise in the incidence and prevalence of depression globally, treatment options involving traditional Chinese medicine (TCM) are receiving increasing attention. Xiaoyaosan, which is commonly used to treat depression, has been used in clinical practice for more than 1000 years in China. Our previous research has confirmed that Xiaoyaosan (XYS), an herbal TCM prescription, can improve depressive-like behavior by regulating the gut microbes closely related to immune-inflammatory processes, providing a potential basis for the antidepressant actions of XYS. The aim of this research is to investigate the antidepressant mechanism of XYSspecifically, we examined the downregulation of the PI3K/Akt/mTOR signaling pathway, restoration of Th17/Tregs, and reduction of inflammatory responseusing network pharmacology, transcriptomics, 4D proteomics, molecular docking, molecular dynamics simulation, and animal experiments. The chemical components of XYS were obtained using the PubChem database and HERB. The ADMET lab 3.0 drug absorption, distribution, metabolism, excretion, and toxicity prediction tool was used to screen the potential ingredients of the compound. The Swiss Target Prediction and SEA TCM ingredient target prediction platforms were used to predict the targets of potential active ingredients. The STRING database was used for protein-protein interaction (PPI) network analysis of the target. A chronic immobilization stress (CIS) rodent model of depression was established using male Sprague-Dawley rats ( = 75). Tests for depressive-like behaviors included the sucrose preference test, open field test, and forced swim test. Transcriptomics and 4D-DIA proteomics were employed to explore gene and protein expression changes in the colon tissue. Molecular docking and molecular dynamics simulations verify the binding of XYS's components and core targets. Rat colons were processed for Western blot detection of PI3K, p-PI3K, mTOR, p-mTOR, Akt, p-Akt, and Th17/Treg-related receptors (RORγ and Foxp3) and for RT-PCR detection of PI3K, mTOR, Akt, RORγt, and Foxp3. Flow cytometry was used to detect Th17 and Treg cell subsets in the colon, and ELISA was applied to detect IL-1 β, TNF-α, IL-17, IL-21, IL-22, IL-10, and TGF-β levels. The core components and core targets were screened by network pharmacology, which combined with molecular dynamics simulation, molecular docking, 4D proteomics, and transcriptomics sequencing revealed that the PI3k/Akt/mTOR signaling pathway is an important pathway underlying the antidepressant effects of XYS. XYS administration ameliorated depressive-like behavior and reduced weight loss in rats with CIS. Western blotting and RT-qPCR experiments showed that compared with the CIS model group, the expression of p-PI3K, p-mTOR, p-Akt, and RORγt was reduced, while that of Foxp3 was increased, in the H-XYS group. Moreover, flow cytometry suggested restored Th17/Treg balance in the colon, while ELISA indicated reduced TNF-α, IL-21, IL-22, IL-17, and IL-1β but increased IL-10 and TGF-β levels in the colons of rats in the H-XYS group. Network pharmacology, combined with 4D proteomics, transcriptomics, molecular docking, molecular dynamics simulation, and in vivo experiments, was performed to explore the antidepressant mechanism of XYS. XYS downregulated the PI3K/Akt/mTOR signaling pathway to restore Th17/Treg balance, reduce the release of proinflammatory factors, and ameliorate depressive behaviors in a CIS rat model.